Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI ACWI ETF (ACWI) vs Becton Dickinson and Co (BDX) Price & Performance

iShares MSCI ACWI ETFTrade
Becton Dickinson and CoTrade

Price performance (Past 24H)

Key statistics

iShares MSCI ACWI ETF vs Becton Dickinson and Co — how do they compare? iShares MSCI ACWI ETF trades at $161.26, while Becton Dickinson and Co trades at $181.29 (market cap $48.93B). The key difference: Becton Dickinson and Co pays a 2.34% dividend while iShares MSCI ACWI ETF pays none. Which is the better fit depends on your goals.

ACWIBDX
52-Week High
$161.44$185.39
52-Week Low
$132.04$138.62
Market Cap
$48.93B
Sector
Health
Enterprise Value
$65.03B
Dividend Yield
2.34%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI ACWI ETF

ACWI (iShares MSCI ACWI ETF) trades at $161.44, up 0.84% with a bullish technical signal from moving averages, though oscillators show caution. The ETF benefits from strong global earnings growth and a forward P/E of 15.5x as of Seeking Alpha on July 7, 2026. Recent institutional activity includes Bank of New York Mellon adjusting its stake, reflecting ongoing investor interest in global equity exposure, particularly in technology sectors.

The outlook for ACWI is supported by robust EPS growth and technical momentum, but risks include market volatility and sector concentration. Investors may find opportunity in its diversified global holdings, though overbought conditions near resistance at $162 warrant monitoring for pullbacks to support at $160.

Becton Dickinson and Co

BDX (Becton, Dickinson and Company) trades at $176.86, down 0.12% on the day, with a bullish technical outlook supported by moving averages and strong earnings beats in recent quarters. The company reported Q3 2026 revenue of $5.0 billion, up 4.4% FX-neutral, and raised full-year guidance, though margins faced pressure. Analyst sentiment is mixed with a consensus price target of $183.00, while institutional ownership remains stable amid positive news on GLP-1 therapy expansions and dividend declarations.

The stock offers steady growth potential with a 2.7% dividend yield and consistent earnings outperformance, but risks include margin compression, regulatory recalls, and high valuation multiples. Near-term resistance at $180 and support at $173 will test bullish momentum, with the current price near the consensus target suggesting limited upside without further catalysts.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares MSCI ACWI ETF

The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index is a free float-adjusted market capitalization index designed to measure the combined equity market performance of developed and emerging markets countries.

Read more on ACWI

About Becton Dickinson and Co

Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.

Read more on BDX